1012:
955:
372:
365:
358:
78:
238:
1057:
996:
1091:
1086:
34:
1076:
1050:
989:
914:
324:
307:
Popescu CD, Trofin D, Ignat B, Matei D (2014). "New
Aspects of Therapeutic Management in Alzheimer`s Disease". In Atta-ur-Rahman (ed.).
1101:
1096:
1081:
1043:
982:
350:
445:
293:
135:
931:
381:
570:
565:
919:
826:
259:
1019:
962:
99:
44:
27:
269:
Inc. In
November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.
802:
704:
603:
474:
320:
1027:
966:
108:
611:
312:
180:
1011:
286:
144:
1023:
925:
580:
1070:
896:
855:
665:
499:
891:
782:
777:
762:
719:
660:
650:
635:
630:
316:
66:
340:
875:
841:
807:
797:
772:
675:
670:
625:
620:
616:
593:
544:
504:
431:
954:
870:
787:
767:
746:
741:
709:
645:
640:
534:
529:
519:
514:
509:
494:
489:
460:
426:
219:
119:
812:
736:
724:
714:
689:
655:
588:
549:
539:
524:
410:
405:
49:
287:"Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab"
20:
731:
61:
266:
164:
53:
258:
is a humanized monoclonal antibody designed for the treatment of
390:
311:. Vol. 3. Sharjah: Bentham Science Publishers. p. 55.
155:
354:
384:
for bone, musculoskeletal, circulatory, and neurologic systems
309:
Frontiers in
Clinical Drug Research: Alzheimer Disorders
1031:
970:
245:
884:
863:
854:
834:
825:
755:
697:
688:
602:
579:
558:
482:
473:
453:
444:
419:
398:
389:
218:
179:
174:
154:
134:
118:
98:
93:
77:
72:
60:
43:
33:
26:
107:
1051:
990:
366:
8:
19:
1058:
1044:
997:
983:
860:
831:
694:
479:
450:
395:
373:
359:
351:
143:
278:
18:
7:
1008:
1006:
951:
949:
163:
1092:Experimental monoclonal antibodies
1087:Anti-amyloid monoclonal antibodies
1030:. You can help Knowledge (XXG) by
969:. You can help Knowledge (XXG) by
14:
1010:
953:
197:
191:
1077:Drugs not assigned an ATC code
317:10.2174/9781681080680115030004
209:
203:
185:
1:
294:American Medical Association
265:Ponezumab was developed by
1118:
1005:
948:
175:Chemical and physical data
1102:Nervous system drug stubs
1097:Monoclonal antibody stubs
1082:Drugs developed by Pfizer
909:
235:
1022:article relating to the
965:–related article is a
827:Angiogenesis inhibitor
963:monoclonal antibody
260:Alzheimer's disease
28:Monoclonal antibody
23:
16:Monoclonal antibody
936:Never to phase III
705:Anti-amyloid drugs
1039:
1038:
978:
977:
946:
945:
905:
904:
850:
849:
821:
820:
684:
683:
469:
468:
440:
439:
326:978-1-68108-068-0
253:
252:
1109:
1060:
1053:
1046:
1014:
1007:
999:
992:
985:
957:
950:
861:
832:
695:
612:Alacizumab pegol
480:
451:
396:
375:
368:
361:
352:
345:
344:
337:
331:
330:
304:
298:
297:
291:
283:
249:
248:
241:
230:
228:
211:
205:
199:
193:
187:
167:
147:
111:
24:
22:
1117:
1116:
1112:
1111:
1110:
1108:
1107:
1106:
1067:
1066:
1065:
1064:
1004:
1003:
947:
942:
941:
926:Clinical trials
901:
880:
846:
817:
751:
680:
598:
575:
554:
465:
446:Musculoskeletal
436:
415:
385:
379:
349:
348:
339:
338:
334:
327:
306:
305:
301:
289:
285:
284:
280:
275:
244:
242:
239:(what is this?)
236:
226:
224:
214:
208:
202:
196:
190:
170:
150:
130:
114:
89:
17:
12:
11:
5:
1115:
1113:
1105:
1104:
1099:
1094:
1089:
1084:
1079:
1069:
1068:
1063:
1062:
1055:
1048:
1040:
1037:
1036:
1024:nervous system
1015:
1002:
1001:
994:
987:
979:
976:
975:
958:
944:
943:
940:
939:
938:
937:
934:
923:
917:
911:
910:
907:
906:
903:
902:
900:
899:
894:
888:
886:
882:
881:
879:
878:
873:
867:
865:
858:
852:
851:
848:
847:
845:
844:
838:
836:
829:
823:
822:
819:
818:
816:
815:
810:
805:
800:
795:
790:
785:
780:
775:
770:
765:
759:
757:
753:
752:
750:
749:
744:
739:
734:
729:
728:
727:
722:
717:
712:
701:
699:
692:
686:
685:
682:
681:
679:
678:
673:
668:
663:
658:
653:
648:
643:
638:
633:
628:
623:
614:
608:
606:
600:
599:
597:
596:
591:
585:
583:
577:
576:
574:
573:
568:
562:
560:
556:
555:
553:
552:
547:
542:
537:
532:
527:
522:
517:
512:
507:
502:
497:
492:
486:
484:
477:
471:
470:
467:
466:
464:
463:
457:
455:
448:
442:
441:
438:
437:
435:
434:
429:
423:
421:
417:
416:
414:
413:
408:
402:
400:
393:
387:
386:
380:
378:
377:
370:
363:
355:
347:
346:
332:
325:
299:
277:
276:
274:
271:
251:
250:
233:
232:
222:
216:
215:
212:
206:
200:
194:
188:
183:
177:
176:
172:
171:
169:
168:
160:
158:
152:
151:
149:
148:
140:
138:
132:
131:
129:
128:
124:
122:
116:
115:
113:
112:
104:
102:
96:
95:
91:
90:
88:
87:
83:
81:
75:
74:
70:
69:
64:
58:
57:
47:
41:
40:
39:Whole antibody
37:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
1114:
1103:
1100:
1098:
1095:
1093:
1090:
1088:
1085:
1083:
1080:
1078:
1075:
1074:
1072:
1061:
1056:
1054:
1049:
1047:
1042:
1041:
1035:
1033:
1029:
1025:
1021:
1016:
1013:
1009:
1000:
995:
993:
988:
986:
981:
980:
974:
972:
968:
964:
959:
956:
952:
935:
933:
930:
929:
927:
924:
921:
918:
916:
913:
912:
908:
898:
897:Landogrozumab
895:
893:
890:
889:
887:
883:
877:
874:
872:
869:
868:
866:
862:
859:
857:
856:Growth factor
853:
843:
840:
839:
837:
833:
830:
828:
824:
814:
811:
809:
806:
804:
801:
799:
796:
794:
791:
789:
786:
784:
781:
779:
776:
774:
771:
769:
766:
764:
761:
760:
758:
754:
748:
745:
743:
740:
738:
735:
733:
730:
726:
723:
721:
718:
716:
713:
711:
708:
707:
706:
703:
702:
700:
696:
693:
691:
687:
677:
674:
672:
669:
667:
666:Ralpancizumab
664:
662:
659:
657:
654:
652:
649:
647:
644:
642:
639:
637:
634:
632:
629:
627:
624:
622:
618:
615:
613:
610:
609:
607:
605:
601:
595:
592:
590:
587:
586:
584:
582:
578:
572:
569:
567:
564:
563:
561:
557:
551:
548:
546:
543:
541:
538:
536:
533:
531:
528:
526:
523:
521:
518:
516:
513:
511:
508:
506:
503:
501:
500:Ascrinvacumab
498:
496:
493:
491:
488:
487:
485:
481:
478:
476:
472:
462:
459:
458:
456:
452:
449:
447:
443:
433:
430:
428:
425:
424:
422:
418:
412:
409:
407:
404:
403:
401:
397:
394:
392:
388:
383:
376:
371:
369:
364:
362:
357:
356:
353:
342:
336:
333:
328:
322:
318:
314:
310:
303:
300:
295:
288:
282:
279:
272:
270:
268:
263:
261:
257:
247:
240:
234:
223:
221:
217:
184:
182:
178:
173:
166:
162:
161:
159:
157:
153:
146:
142:
141:
139:
137:
133:
126:
125:
123:
121:
117:
110:
106:
105:
103:
101:
97:
92:
85:
84:
82:
80:
76:
73:Clinical data
71:
68:
65:
63:
59:
55:
51:
48:
46:
42:
38:
36:
32:
29:
25:
1032:expanding it
1017:
971:expanding it
960:
892:Domagrozumab
792:
783:Galcanezumab
778:Fremanezumab
763:Bapineuzumab
720:Gantenerumab
661:Idarucizumab
651:Etaracizumab
636:Caplacizumab
631:Brolucizumab
335:
308:
302:
281:
264:
255:
254:
243:
237:
109:1178862-65-1
67:beta-amyloid
922:from market
876:Trevogrumab
842:Ranibizumab
808:Solanezumab
803:Semorinemab
798:Refanezumab
773:Eptinezumab
676:Vanucizumab
671:Tadocizumab
626:Bococizumab
621:Ranibizumab
617:Bevacizumab
594:Volociximab
545:Ramucirumab
505:Bentracimab
475:Circulatory
432:Romosozumab
382:Monoclonals
231: g·mol
94:Identifiers
1071:Categories
871:Bimagrumab
788:Ozanezumab
768:Crenezumab
747:Opicinumab
742:Fulranumab
710:Aducanumab
690:Neurologic
646:Emicizumab
641:Demcizumab
535:Nesvacumab
530:Inclacumab
520:Evolocumab
515:Evinacumab
510:Enoticumab
495:Alirocumab
490:Abelacimab
461:Stamulumab
427:Blosozumab
341:"Alzforum"
273:References
220:Molar mass
145:1TG15H1XE9
120:ChemSpider
100:CAS Number
932:Phase III
920:Withdrawn
885:Humanized
835:Humanized
813:Tanezumab
793:Ponezumab
756:Humanized
737:Fasinumab
725:Lecanemab
715:Donanemab
656:Faricimab
604:Humanized
589:Abciximab
571:Imciromab
566:Biciromab
550:Rinucumab
540:Orticumab
525:Icrucumab
420:Humanized
411:Denosumab
406:Burosumab
256:Ponezumab
50:Humanized
21:Ponezumab
732:Erenumab
581:Chimeric
246:(verify)
79:ATC code
181:Formula
915:WHO-EM
323:
267:Pfizer
165:D09952
62:Target
52:(from
45:Source
1026:is a
1018:This
961:This
864:Human
698:Human
559:Mouse
483:Human
454:Human
399:Human
290:(PDF)
195:10158
54:mouse
1028:stub
1020:drug
967:stub
391:Bone
321:ISBN
207:2090
201:1730
189:6552
156:KEGG
136:UNII
127:none
86:none
35:Type
313:doi
229:.48
227:272
225:148
1073::
928::
319:.
292:.
262:.
213:52
1059:e
1052:t
1045:v
1034:.
998:e
991:t
984:v
973:.
619:/
374:e
367:t
360:v
343:.
329:.
315::
296:.
210:S
204:O
198:N
192:H
186:C
56:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.